anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Older adults with chronic or acute cognitive impairment, such as dementia or delirium, who are hospitalized face unique barriers to person-centered care and a higher risk for negative outcomes stemming from hospitalizations. There is a need for co-designed interventions adapted for these patients to the hospital setting to improve care and outcomes. Patient life storytelling interventions have demonstrated promise in enhancing person-centered care by improving patient-care team relationships and providing information to enable care tailored to individual needs and values.
OBJECTIVE: This study aims to engage patients, care partners, and clinical stakeholders in a co-design process to adapt an existing life storytelling model for use with older adults with dementia and at risk of delirium in the acute care hospital setting.
METHODS: We recruited patients with dementia or at risk of delirium who were hospitalized, their care partners, clinicians, and informaticists. A 3-stage co-design process that used a mixed methods data collection approach including in-depth interviews and surveys was completed. We used content analysis to analyze qualitative data and descriptive statistics to summarize quantitative data.
RESULTS: In total, 27 stakeholder informants (ie, patients, care partners, and interdisciplinary care team [IDT] members) participated. Stakeholders were unanimously interested in using patient life stories as a tool for hospital care through electronic health record (EHR) integration. Stakeholders shared potential topics for life stories to cover, including social support, information on patients' key life events, and favorite activities. Participants provided insights into the logistics of integrating life stories into acute care, including interview arrangement, story-sharing methods, and barriers and facilitators. IDT members shared preferences on EHR integration, resulting in 3 co-designed mock-ups of EHR integration options. Stakeholders shared ways to optimize future acceptability and uptake, including engaging with the care team and promoting awareness of life stories, ensuring suitability to the acute environment (eg, distilling information in an easily digestible way), and addressing concerns for patient capacity and privacy (eg, engaging care partners when appropriate). Thoughts on potential impacts of life stories were also elicited, including improving patient- and care partner-IDT member relationships; humanizing patients; increasing clinical team, patient, and caregiver satisfaction; and enabling more specific, tailored care for patients with dementia and at risk of delirium.
CONCLUSIONS: This study resulted in a co-designed life storytelling intervention for patients with dementia and at risk for delirium in an acute care hospital setting. Stakeholders provided valuable information to ensure future intervention acceptability and uptake, including potential benefits, facilitators, and challenges in the acute care setting.
Patients in this group will receive conventional chest physiotherapy, two times a day, 7 days a week for 8 weeks. One exercise session will be supervised in a clinic per week, other sessions will be performed at home.
PURPOSE:To measure metallothioneine with high sensitivity by conjugating the metallothioneine and tyrosine ith a specific binder, conjugating the same with radioactive iodine to prepare labeled metallothioneine and using the same in radioimmunoassay. CONSTITUTION:Metallothioneine and tyrosine are conjugated by the binder expressed by the formula (for example, m-maleimidebenzoyl-N-hydroxysuccinimide ester). Radioactive iodine is conjugated therewith to prepare labeled mettalothioneine-binder-tyrosine (labeled antigen). This labeled antigen and metallothioneine antibody are mixed with a specimen having metallothioneine (antibody) to conjugate the antigen and the antibody. The conjugate thereof is subjected to a radioimmunoassay by which the labeled metallothioneine is measured. The measured value and the preliminarily determined standard value of a standard sample are compared and the amt. of the metallothioneine in the specimen is determined. The metallothioneine in a living body is thus detected with high accuracy by using the labeled metallothioneine and the poisoning disease with heavy metals is diagnosed in an early period.
Instrumentation with manual files shall be performed with balanced forces (Roane) technique consist of placing the instrument as apically as it can go and then turning it clockwise (less than 180º). This is followed by a counterclockwise rotation (of at least 120º) with slight apical pressure. This is repeated until the desired working length is obtained.
BACKGROUND: The prediction of Alzheimer's disease (AD) progression from its early stages is a research priority. In this context, the use of Artificial Intelligence (AI) in AD has experienced a notable surge in recent years. However, existing investigations predominantly concentrate on distinguishing clinical phenotypes through cross-sectional approaches. This study aims to investigate the potential of modeling additional dimensions of the disease, such as variations in brain metabolism assessed via [18F]-fluorodeoxyglucose positron emission tomography (FDG-PET), and utilize this information to identify patients with mild cognitive impairment (MCI) who will progress to dementia (pMCI).
METHODS: We analyzed data from 1,617 participants from the Alzheimer's Disease Neuroimaging Initiative (ADNI) who had undergone at least one FDG-PET scan. We identified the brain regions with the most significant hypometabolism in AD and used Deep Learning (DL) models to predict future changes in brain metabolism. The best-performing model was then adapted under a multi-task learning framework to identify pMCI individuals. Finally, this model underwent further analysis using eXplainable AI (XAI) techniques.
RESULTS: Our results confirm a strong association between hypometabolism, disease progression, and cognitive decline. Furthermore, we demonstrated that integrating data on changes in brain metabolism during training enhanced the models' ability to detect pMCI individuals (sensitivity=88.4%, specificity=86.9%). Lastly, the application of XAI techniques enabled us to delve into the brain regions with the most significant impact on model predictions, highlighting the importance of the hippocampus, cingulate cortex, and some subcortical structures.
CONCLUSION: This study introduces a novel dimension to predictive modeling in AD, emphasizing the importance of projecting variations in brain metabolism under a multi-task learning paradigm.
Cystic fibrosis (CF) may cause a spectrum of hepatobiliary complications, including portal hypertension, multilobular cirrhosis, and liver failure. Current guidelines on the detection and monitoring of hepatobiliary complications in CF were published in 1999. The CF Foundation assembled a committee to evaluate research advances and formulate revised guidelines for CF-associated liver disease. A committee of hepatologists, gastroenterologists, pulmonologists, pharmacists, nurses, dietitians, individuals with CF, and the parents of a child with CF devised "population, intervention, comparison, and outcome" questions regarding hepatobiliary disease in CF. PubMed literature searches were performed for each population, intervention, comparison, and outcome question. Recommendations were voted on with 80% agreement required to approve a recommendation. Public comment on initial recommendations was solicited prior to the formulation of final recommendations. Thirty-one population, intervention, comparison, and outcome questions were assembled, 6401 manuscripts were title screened for relevance, with 1053 manuscripts undergoing detailed full-text review. Seven recommendations were approved for screening, 13 for monitoring of existing disease, and 14 for treatment of CF-associated hepatobiliary involvement or advanced liver disease. One recommendation on liver biopsy did not meet the 80% threshold. One recommendation on screening ultrasound was revised and re-voted on. Through a multidisciplinary committee and public engagement, we have assembled updated recommendations and guidance on screening, monitoring, and treatment of CF-associated hepatobiliary involvement and advanced liver disease. While research gaps remain, we anticipate that these recommendations will lead to improvements in CF outcomes through earlier detection and increased evidence-based approaches to monitoring and treatment.
Randomization of subjects will be performed at the end of 7 days of sensitive intravenous antibiotic administration, provided the subjects meet randomization criteria. Those who are randomized to the 7-day group will not receive any further antibiotics.
PURPOSE: A pharmaceutical composition containing EGCG(epigallocatechin gallate) is provided to suppress differentiation of cytotoxic Th17 cells and to prevent or treat Sjogren syndrome, Behcet syndrome, or lupus. CONSTITUTION: A composition for preventing or treating Sjogren syndrome, Behcet syndrome, or lupus contains EGCG(epigallocatechin gallate) compound or salt thereof as an active ingredient. The EGCG suppresses or reduces differentiation of undifferentiated T cells into Th17 cells. A method for activating regulatory T cells comprises a step of treating the EGCG compounds or salt thereof to the T cells(Treg) in vitro. A functional food for treating or preventing Sjogren syndrome, Behcet syndrome, or lupus contains the EGCG compound or salt thereof as an active ingredient. A composition for suppressing immunity contains the EGCG compounds or salt thereof as an active ingredient.
Disclosed in the present invention is a method for treating bone and joint diseases due to abnormal neovascularization using nintedanib, comprising: preparing nintedanib into a medicament by adding auxiliary materials, and systemically or locally administrating the medicament to body parts affected by bone and joint diseases to accelerate recovery from bone and joint diseases. The bone and joint diseases due to abnormal neovascularization comprise degenerative arthritis, bursitis, synovitis, and cervical spondylosis. The bone and joint diseases due to abnormal neovascularization comprise lumbar spondylosis, frozen shoulder and the like. An external preparation is one of a solution, a suspension, a cream, an ointment, a gel, gel-forming liquid, etc., and an oral preparation. The oral preparation comprises a tablet, a sustained release tablet, or liquid. In the present application, the use of nintedanib to the clinical treatment of bone and joint diseases due to abnormal neovascularization can help patients recover as soon as possible. In the present invention, new medical use and a new application field of nintedanib are explored, providing great significance for the treatment of bone and joint diseases due to abnormal neovascularization.
The present invention discloses methodologies for negative selection of specific phagocytic cells from a heterogeneous population of cells derived from bone marrow and/or peripheral blood utilizing a ferrous-based, preferably carbonyl iron, magnetic selection techniques. Carbonyl iron (CI) selection allows for efficient removal, via the use of a high-energy magnet (e.g., samarium cobalt), of cells such as macrophages, monocytes, and neutrophils without any associated decrease in the number of hematopoietic CD34+ stem or myeloid progenitor cells. CI selection results in the removal of > 40 % of the total number of cells, and a concomitant removal of > 85 % of monocytes in bone marrow samples. Similarly, in peripheral blood samples, CI selection results in the removal of 68 % of the total number of cells, with a concomitant 6-fold enrichment of CD34+. Moreover, when CI selection is combined with Ficoll-Hypaque density gradient centrifugation, a depletion of > 85 % of total cell number and a concomitant 9-fold enrichment of CD34+ cells is found in peripheral blood samples. Following carbonyl iron selection, the enriched cell population may then be subjected to further positive selection of hematopoietic CD34+ stem/progenitor cells and/or negative selection of contaminating, malignant cells utilizing magnetic immunobead methodology.
Participants did not receive any study treatment in this arm but were on continued active surveillance (AS) for 1 year of treatment period. Following the 1-year treatment period, all participants were followed for 1 additional year. Post the 1-year follow up, participants then started the continued follow-up period, in which, participants were followed up every 3 months for these 2 years, after which follow-up was either every 6 months up to 36 months or until the end of study (total duration of follow up in the study was approximately up to 35.9 months).
PURPOSE: A novel fusarisetin compound isolated from Fusarium sp. fungus FN080326 is provided to suppress proliferation of cancer cells such as liver cancer cells, breast cancer cells, and myeloid leukemia cells. CONSTITUTION: A novel fusarisetin compound is denoted by chemical formula 1. A fusarisetin A compound is denoted by chemical formula 2 or 3. The fusarisetin compound is isolated from Fusarium sp. FN08026. A pharmaceutical composition for preventing and treating cancer contains the fusarisetin compound or pharmaceutically acceptable salt threreof as an active ingredient. A method for preparing the fusarisetin compound comprises: a step of culturing Fusarium sp. FN080326; and a step of isolating the fusarisetin compound from strain culture.
Two sessions of CPT (morning and afternoon, 20 minutes each) were conducted. The CPT session consisted of modified postural drainage, assisted cough technique, positive expiratory pressure and chest percussion, vibration. The appointed therapist performed pulmonary auscultation and thoracic palpation to assess the status of pulmonary ventilation and secretion retention, and whether the patient's cough ability can complete effective airway clearance. Individualized program was formed according to the assessment, internal guidelines, the patient's tolerance, education level, and patient's preference prior to the randomization. All CPT sessions were performed by the same physiotherapist to avoid potential bias.
PURPOSE:To obtain the subject protein in high recovery and colorless state by carrying out the cultivation and purification in the manifestation of human serum albumin by gene manipulation technique in the presence of alkylamines, guanidines, benzamidines, basic amino acids, etc. CONSTITUTION:A recombinant plasmid prepared by binding a gene coding human serum albumin(HSA) to a manifestation vector is inserted into a host such as Saccharomyces cerevisiae TMS33-1h4. The culture of the transformant and the separation and purification of the product from the culture liquid are carried out in the presence of an amine compound such as an alkylamine (e.g. methylamine, ethylamine and propylamine), a diamine (e.g. ethylenediamine and propylenediamine), a guanidine compound (e.g. guanidine and aminoguanidine), a benzodiamine compound (e.g. benzodiamine and p- aminobenzodiamine), a basic amino acid (e.g. lysine and arginine) and aminophenylacetic acid to obtain the objective HSA while suppressing the coloration.
INTRODUCTION: Older age is associated with greater likelihood of urinary incontinence and unmet care needs. It was hypothesized that age might influence clinical and ultrasound outcomes of transobturator mid-urethral sling (TOS) surgery. The aim of this study was to compare 1-year postoperative clinical and ultrasonographic outcomes of TOS surgery among women of different ages.
METHODS: A retrospective analysis of a cohort of women who underwent primary and isolated TOS surgery for uncomplicated urodynamic stress incontinence was undertaken. All women underwent pre-operative and 1-year postoperative evaluations including clinical interview, pelvic examination, urodynamic studies and introital four-dimensional ultrasound. To be eligible for surgery, women needed to be independent in their daily life, and to have an acceptable level of surgical risk on pre-operative assessment. The primary outcome was the rate of stress urinary incontinence (SUI) after surgery. The secondary outcomes comprised postoperative adverse events and ultrasound findings.
RESULTS: In total, 162, 213, 60 and 29 women aged <51, 51-64, 65-74 and ≥75 years, respectively, were included in this study. At 1-year postoperative assessment, older women were more likely to report SUI and bothersome SUI, while the severity of SUI and postoperative adverse events were similar in older women compared with other age groups. Ultrasound revealed that the sling tended to be looser and higher in older women.
CONCLUSION: TOS surgery is effective and safe for women of all ages who are independent in their daily life and who have an acceptable level of surgical risk. The sling tended to be looser and higher in older women.
Patients with CIDP successfully treated with IVIg/SCIg for under 12 months. Subjects will receive an intravenous infusion of 1,000mg Rituximab at Week 0 and Week 2.
Although the lateral internal sphincterotomy is the treatment of choice for CAF, it has several drawbacks. First, the lower portion of the internal sphincter is nested in the lowermost part of the anus. Thus, an incision from the fissure base up to the dentate line removes support to the inner sphincter structure on the incision site. In our opinion; this is the main cause of different levels of incontinence developing in the postoperative period. Second, the internal sphincter muscle is shorter in women than in men. Therefore, women are at higher risk of postoperative anal incontinence than men. Third, because the lateral internal sphincterotomy is not standardized, the length of the internal sphincter incision varies, depending on the surgeon's discretion and competency. Fourth, an incision that is too short increases in the risk of recurrence.

The investigators believe that this observation could be explained by the fact that the length of the incision required for a lateral internal sphincterotomy procedure has not been standardized
The present invention relates to neurotrophin-3(NT-3), a newly discovered member of the BDNF gene family. It is based, in part, on the identification of regions of nucleic acid sequence homology shared by BDNF and NGF. According to the present invention, these regions of homology may be used to identify new members of the BDNF/NGF gene family; such methodology was used to identify NT-3. The present invention provides for the genes and gene products of new BDNF/NGF related neurotrophic factors identified by these methods. According to the invention, NT-3 may be used in the diagnosis and/or treatment of neurologic disorders, including, but not limited to, Alzheimer's disease and Parkinson's disease. Because NT-3 has been observed to exhibit a spectrum of activity different from the specificities of BDNF or NGF, NT-3 provides new and valuable options for enduring regrowth and repair in the central nervous system.
The invention relates to a kunjing expandable vaginal suppository, and a preparation method and a detection method thereof. The expandable vaginal suppository comprises a traditional Chinese medicine extract, furazolidone, a matrix and an expansion carrier. The traditional Chinese medicine composition, furazolidone and the matrix form a drug-containing matrix, which is coated on the surface of the expansion carrier. The traditional Chinese medicine extract is mainly prepared from Radix Bupleuri and Edelweiss through extraction; and the traditional Chinese medicine extract also includes fructus kochiae and Pulsatilla. The stearic acid and sodium dextran in the drug-containing matrix can cooperate to promote absorption of the traditional Chinese medicine extract and furazolidone and improve the bioavailability of the expandable vaginal suppository; glucan can also promote the formation of the expandable vaginal suppository; and cellulose acetate prolong curative effect of the expandable vaginal suppository. The kunjing expandable vaginal suppository is an up and down double-layer expandable suppository, employs seven unique technologies, and has the beneficial effects of prevention of outflow liquid, high stability, lasting effect and prevention of secondary infection.
Abnormal expression of the cell cycle inhibitor and p53 target CDKN1A/p21 has been associated with paradoxical outcomes, such as hyperproliferation in p53-deficient cancer cells or hypoproliferation that affects hematopoietic stem cell behavior, leading to bone marrow failure (BMF). Notably, p21 is known to be overexpressed in Fanconi anemia (FA), which is a rare syndrome that predisposes patients to BMF and cancer. However, why p21 is overexpressed in FA and how it contributes to the FA phenotype(s) are still poorly understood. Here, we revealed that while the upregulation of p21 is largely dependent on p53, it also depends on the transcription factor microphthalmia (MITF) as well as on its interaction with the nucleolar protein NPM1. Upregulation of p21 expression in FA cells leads to p21 accumulation in the chromatin fraction, p21 immunoprecipitation with PCNA, S-phase lengthening and genetic instability. p21 depletion in FA cells rescues the S-phase abnormalities and reduces their genetic instability. In addition, we observed that reactive oxygen species (ROS) accumulation, another key feature of FA cells, is required to trigger an increase in PCNA/chromatin-associated p21 and to impact replication progression. Therefore, we propose a mechanism by which p21 and ROS cooperate to induce replication abnormalities that fuel genetic instability.
In this case report, we present an unusual clockwise torsion of left colon around mesenteric root in a 10-month-old Arab filly, highlighting the clinical presentation, diagnostic approach and successful surgical intervention. A 10-month-old Arab filly weighing approximately 250 kg was referred with signs of acute abdominal pain. The history revealed anorexia, restlessness and severe abdominal pain that had begun the previous day. The local practitioner had previously administered flunixin meglumine, an analgesic, but it proved ineffective in relieving the pain. Upon physical examination, the filly exhibited sweating, a body temperature of 38.5°C, tachycardia (65 beats per minute) and tachypnea (25 breaths per minute). Due to the severity of the colic and the lack of response to the conservative treatments, surgical intervention was deemed necessary. An exploratory midline celiotomy was performed to evaluate the abdominal organs. During the examination, no obvious primary lesions were identified in the evaluated organs. However, a restriction in exteriorizing the left colon's length was observed. Further examination revealed an unusual clockwise torsion of the left colon that displaced in left to the right side around the mesenteric root; thereby, pelvic flexure was located in the normal anatomical position with a short length. To the best of our knowledge, this is the first reported case of clockwise torsion and an atypical displacement of the left colon in horses. The surgical correction of the displacement was successfully performed. The filly showed improvement post-surgery and did not exhibit any complications during the recovery period.